ADVERTISEMENT

Three fledgling life sciences companies are moving into a new University at Buffalo business incubator on the Buffalo Niagara Medical Campus.

The companies are taking space in UB’s Clinical and Translational Research Center, which opened this summer with the goal of speeding up the process of turning research into marketable drugs.

The three companies now moving into UB’s Biosciences Incubator – AccuTheranostics, AndroBioSys and Ceno Technologies – will gain access to researchers working in the new center and elsewhere on the Medical Campus, spurring collaboration and innovation, officials said.

“We expect there will be a considerable number of discoveries coming out of the CTRC over time,” said Woody Maggard, an associate vice provost and incubator manager for UB’s Office of Science, Technology Transfer and Economic Outreach, or STOR. “This is an opportunity to have our services immediately available.”

The Clinical and Translational Research Center takes up the top half of a building at Ellicott and Goodrich streets that UB built with Kaleida Health. The building was designed to encourage interaction among doctors and scientists, and stimulate the translation of basic research into drugs, medical devices and therapies.

The Biosciences Incubator occupies part of the center’s fifth floor, and the three companies will fill the 4,000 square feet of available space, according to UB.

A committee selected the first tenants for the Biosciences Incubator, which, like UB’s Technology Incubator at Baird Research Park in Amherst, is under the auspices of STOR.

The new incubator employs one full-time staff person on-site and boasts offices and wet labs. Tenants pay to rent space but receive free access to specialized equipment and guidance on how to launch, market and raise money for a startup business, the university reported.

The three tenants in the Biosciences Incubator are:

• AccuTheranostics, which moved its three employees from the Baird Research Park incubator as of Sept. 1. The company’s employees are working to develop personalized chemotherapy treatment for cancer patients.

• AndroBioSys will move three employees into the incubator by the end of November. The company grew out of research conducted at Roswell Park Cancer Institute that pursued new methods for detecting and treating prostate cancer as early as possible.

• Ceno Technologies is moving the four employees in its growing Bio Division from the company’s current location in the nearby Innovation Center, where the rest of the company will remain and expand, said CEO Scottpatrick J. Sellitto. Ceno produces high-tech coatings used on microscopic particles with applications for the military, manufacturing and drug development.

email: swatson@buffnews.com